Viridian Therapeutics Announces Positive Topline Results from Elegrobart Phase 3 REVEAL‑1 Clinical Trial in Active Thyroid Eye Disease

Viridian Therapeutics Announces Positive Topline Results from Elegrobart Phase 3 REVEAL‑1 Clinical Trial in Active Thyroid Eye Disease

WALTHAM, Mass.--(BUSINESS WIRE)--Mar 30, 2026-

BioRestorative Reports Positive Phase 2 Data for BRTX-100 in Chronic Lumbar Disc Disease - Business News Week

BioRestorative Therapies Reports Positive  Phase 2 Blinded Data for BRTX-100 Demonstrating Meaningful Improvements in Pain and Function in Chronic Lumbar Disc Disease MELVILLE, N.Y., March 30, 2026 — BioRestorative Therapies, Inc. (“BioRestorative,” “BRTX,” or the “Company”) (Nasdaq:BRTX), a late-stage clinical regenerative medicine company focused on stem cell-based therapies and products, today announced blinded data from its […] The post BioR…

Viridian’s autoimmune eye disease shot passes Phase 3, but can it compete with Amgen?

Viridian Therapeutics' shares dropped Monday morning after a lackluster pivotal readout on its injection to treat thyroid eye disease. Viridian’s pitch is that its drug, known as elegrobart, comes as an injection that can be ...

Viridian Therapeutics’ stock sinks despite positive Phase III TED data

Viridian’s stock fell despite elegrobart meeting its primary endpoints in a Phase III trial.The post Viridian Therapeutics’ stock sinks despite positive Phase III TED data appeared first on Clinical Trials Arena.

Viridian’s thyroid eye disease drug succeeds in late‑stage trial but falls short of expectations - Regional Media News

By Siddhi Mahatole March 30 (Reuters) - Viridian Therapeutics said on Monday its experimental drug met the main goal in a late-stage study, when tested in patients with active thyroid eye disease. Shares of the company, however, fell 36% in premarket trading. Jefferies analyst Faisal Khurshid said the data reduces risk for Viridian since it now has two potential thyroid eye disease drugs, but there could be "fierce investor debate on commercial …

Viridian Reports Positive Phase 3 Data for Subcutaneous TED Therapy, Eyes Regulatory Filing

Key Takeaways Viridian’s Phase 3 REVEAL-1 trial met its primary endpoint, showing statistically significant and clinically meaningful reductions in proptosis with subcutaneous elegrobart in active thyroid eye disease The therapy demonstrated a favorable safety profile and the potential for convenient at-home administration Viridian plans to submit a BLA for elegrobart in Q1 2027 Viridian Therapeutics announced positive topline results from its…